Hillsdale Investment Management Inc. increased its position in Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 7.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 331,300 shares of the company’s stock after purchasing an additional 23,100 shares during the period. Hillsdale Investment Management Inc.’s holdings in Pacira BioSciences were worth $7,487,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. Northwestern Mutual Wealth Management Co. raised its stake in Pacira BioSciences by 5,900.0% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,500 shares of the company’s stock valued at $39,000 after buying an additional 1,475 shares during the last quarter. Kestra Advisory Services LLC purchased a new position in shares of Pacira BioSciences in the 4th quarter worth $48,000. Eurizon Capital SGR S.p.A. bought a new stake in shares of Pacira BioSciences during the 4th quarter valued at about $51,000. Global Retirement Partners LLC grew its position in Pacira BioSciences by 479.4% during the fourth quarter. Global Retirement Partners LLC now owns 2,028 shares of the company’s stock valued at $52,000 after buying an additional 1,678 shares during the period. Finally, Hantz Financial Services Inc. increased its stake in shares of Pacira BioSciences by 127.3% in the 4th quarter. Hantz Financial Services Inc. now owns 2,573 shares of the company’s stock worth $67,000 after purchasing an additional 1,441 shares in the last quarter. Institutional investors own 99.73% of the company’s stock.
Pacira BioSciences Price Performance
NASDAQ PCRX opened at $25.54 on Tuesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.35 and a current ratio of 4.73. The company has a market cap of $1.00 billion, a PE ratio of 212.85 and a beta of 0.27. The firm’s 50 day moving average price is $23.69 and its 200-day moving average price is $23.19. Pacira BioSciences, Inc. has a 52-week low of $18.80 and a 52-week high of $27.64.
Insider Buying and Selling at Pacira BioSciences
In other news, CFO Shawn Cross sold 12,941 shares of the company’s stock in a transaction dated Thursday, April 23rd. The shares were sold at an average price of $25.16, for a total transaction of $325,595.56. Following the transaction, the chief financial officer owned 105,341 shares in the company, valued at $2,650,379.56. This represents a 10.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Lauren Riker sold 6,115 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $23.50, for a total transaction of $143,702.50. Following the completion of the transaction, the senior vice president directly owned 62,284 shares of the company’s stock, valued at approximately $1,463,674. This represents a 8.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 31,115 shares of company stock worth $771,896 over the last ninety days. Corporate insiders own 6.40% of the company’s stock.
Analysts Set New Price Targets
A number of equities research analysts have commented on the stock. Needham & Company LLC raised their target price on shares of Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, May 1st. Barclays dropped their price target on Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating for the company in a research note on Thursday, March 26th. Zacks Research raised shares of Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 7th. Weiss Ratings raised Pacira BioSciences from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, May 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $38.00 price objective on shares of Pacira BioSciences in a research report on Wednesday, July 1st. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Pacira BioSciences currently has an average rating of “Hold” and an average target price of $29.40.
Check Out Our Latest Research Report on PCRX
Pacira BioSciences Profile
Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.
In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.
Featured Stories
- Five stocks we like better than Pacira BioSciences
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report).
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
-ltd-logo-1200x675.png){kind=logo}
